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Abstract 
Atrial fibrillation (AF) is the most common arrhythmia diagnosed in clinical practice. The consequences of AF have been clearly estab-
lished in multiple large observational cohort studies and include increased stroke and systemic embolism rates if no oral anticoagulation is 
prescribed, with increased morbidity and mortality. With the worldwide aging of the population characterized by a large influx of “baby 
boomers” with or without risk factors for developing AF, an epidemic is forecasted within the next 10 to 20 years. Although not all studies 
support this evidence, it is clear that AF is on the rise and a significant amount of health resources are invested in detecting and managing AF. 
This review focuses on the worldwide burden of AF and reviews global health strategies focused on improving detection, prevention and risk 
stratification of AF, recently recommended by the World Heart Federation.    
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1  Introduction 
As the population ages globally, atrial fibrillation (AF) is 
predicted to affect 6–12 million people in the USA by 2050 
and 17.9 million in Europe by 2060.[1–3] AF utilizes signifi-
cant health resources globally,[4] and constitutes a public 
health challenge with high comorbidity,[5] and increased 
mortality risk.[6] The reasons for the increase in the preva-
lence of AF remain elusive[7,8] and are related to multiple 
factors including; enhanced detection, increased incidence, 
and greater survival after onset of AF.[9–11] The purpose of 
this review is to assess the evidence related with the in-
creased overall prevalence of AF and to propose a global 
strategy focused on enhanced detection and multidiscipli-
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nary management of AF envisioned by the World Heart 
Federation.[1,2,7–12] 
2  AF global burden 
AF is the most frequently encountered arrhythmia in 
clinically practice.[3] Between 1990 and 2013, although the 
global prevalence rate of AF decreased slightly, the overall 
number of AF cases increased (Table 1).[13] AF is associated 
with an increase in morbidity, as measured by disability- 
adjusted life years (DALYs). Estimates of prevalence of AF, 
and DALYs associated with AF, are likely to underestimate 
true burden due to the high prevalence of asymptomatic 
AF.[3] AF also leads to increased health care resource utili-
zation and may have a significant impact on global health 
budgets.[14–17] Several long-term cohorts have clearly estab-
lished that several clinical outcomes are increased in pa-
tients with AF.[18] Among other clinical outcomes, AF is 
associated with increased risk of stroke and is found in one 
third of all ischemic strokes.[19] 
AF burden has regional variations, with high-income 
countries experiencing a higher prevalence, incidence, 
DALYs and mortality associated with AF than low-middle  
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income countries (LMIC).[3] However, estimates of the ex-
tent of this difference should be interpreted with caution, as 
Table 1.  Global burden of AF in 1990 and 2013, data from 
Global Burden of Disease Study 2013.[13] 
Global  
Prevalence 
*Cases (All ages) 
Rate per 100,000 
(Age-standardized) 
Year Mean 95% UI  Mean 95% UI  
1990 6841147 (6602764, 7114686) 213.7 (205.9, 222.6) 
2013 11178627 (10655102, 11683727) 191.3 (182.1, 200.1) 
Global  
DALYs 
*Cases (All ages) 
Rate per 100,000 
(Age-standardized) 
Year Mean 95% UI Mean 95% UI  
1990 854714 (693332, 1049075) 26.7 (21.7, 32.7) 
2013 1888690 (1590032, 2224863) 32.5 (27.5, 38.2) 
*Cases rounded to the nearest whole number. DALYs: disability-adjusted 
life years; UI: uncertainty interval. 
the lower rates of AF documented in developing countries 
may be related to under reporting, limited access to health 
care services and geographical disparity in published data.[3,20] 
Estimating the global burden of AF is challenging and 
few studies have systematically reviewed population-based 
AF studies (Figure 1). Chugh, et al.,[3] reviewed all popula-
tion based AF studies between 1980 to 2010, from 21 global 
burden of disease regions. These investigators estimated 
global/regional prevalence, incidence, and morbidity and 
mortality related to AF. The estimated number of individu-
als with AF globally in 2010, was 33.5 million (20.9 million 
men and 12.6 million women) with significant regional 
variations and heterogeneity (Table 1). Mortality associated 
with AF was increased by 2-fold in both genders from 1990 
to 2010 (Figures 2–4).[3]  
 
Figure 1.  Global age-adjusted prevalence rates of AF (per 100,000 persons). Reproduced with permission from Chugh, et al.[3] AF: 
atrial fibrillation. 
 
Figure 2.  Mortality associated with AF: 1990–2010 (per 100,000 persons). Reproduced with permission from Chugh, et al.[3] AF: atrial 
fibrillation; UI: uncertainty interval.   
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Figure 3.  Mortality associated with AF by gender and region (developed vs. developing). Reproduced with permission from Chugh, et 
al.[3] AF: atrial fibrillation. 
 
Figure 4.  Global mortality associated with AF in 2010. Colors represent percentages. Reproduced with permission from Chugh, et al.[3] 
AF: atrial fibrillation. 
Furthermore, in all countries regardless of development, 
a substantial proportion of AF cases are subclinical,[21] lim-
iting the ability to appropriately identify and detect AF 
without advanced medical technology. Recent data from 
the ASSERT II trial suggests that the prevalence of sub-
clinical AF > 5 min in subjects over 65 years with either a 
CHA2DS2VASc ≥ 2, sleep apnoea or body mass index 
(BMI) > 30 kg/m2 with no evidence of clinical AF is around 
30%, indicating that subclinical AF may be detected in al-
most 1/3 of the population that otherwise has a low-inter-
mediate risk of developing symptomatic AF and subsequent 
AF associated comorbidities.[22] 
The occurrence of death and stroke in patients presenting 
to a hospital emergency department vary widely across 
geographical regions. The RELY-AF Registry recently re-
ported the 1-year mortality and stroke rates in patients from 
47 countries.[23] Marked and unexplained differences in 
mortality and stroke rates were observed. Over 15,000 indi-
viduals were enrolled and 1758 (11%) died within 1 year. 
Fewer deaths occurred among patients presenting to the 
emergency department with primary AF compared with 
those with secondary AF, 6% vs. 16% (P < 0.0001). Twice 
as many patients had died by 1 year in South America (17%) 
and Africa (20%) compared with North America, Western 
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Europe, and Australia (10%, P < 0.0001). Heart failure was 
the most common cause of death (30%); stroke caused  
deaths (8%), and 4% patients had had a stroke by 1 year; 
3% of those with primary AF and 5% with secondary AF (P 
< 0.0001). The highest number of strokes occurred in pa-
tients in Africa (8%), China (7%), and Southeast Asia (7%) 
and the lowest occurred in India (< 1%). Only 3% of the 
patients in North America, Western Europe, and Australia 
had a stroke.  
Patients with AF in LMIC tend to be a decade younger, 
are more likely to experience heart failure, and are less 
likely to be managed according to recommended AF guide-
lines (i.e., patients with AF in LMIC have significantly 
lower use of oral anticoagulants (OACs), and lower time in 
therapeutic range which may be related with limited access 
to health care systems.[24] Differences in AF burden among 
LMIC and high-income countries should also be interpreted 
in light of the risk factor profile of this condition. European 
ancestry has been identified as a risk factor for AF (com-
pared to African or Asian ancestry),[25,26] the risk of AF 
mainly increases with age,[27] and is higher among those 
with CVD such as myocardial infarction and CVD risk fac-
tors that include hypertension, diabetes mellitus, obesity, 
smoking, and alcohol use.[25,28–34] Other non-conventional 
risk factor such as sleep apnoea have also been identified as 
potential markers of increased AF prevalence.[35] As these 
risk factors continue to increase in LMIC, likely will the 
burden of morbidity and mortality from AF. This burden 
may be further compounded by the shortage of health care 
resources in many LMIC, as successful management of AF 
requires consistent and long-term interaction between the 
patient and health care system and clear public health poli-
cies addressed to controlling modifiable risk factors such as 
hypertension, obesity, etc. 
3  Primary prevention 
Primary prevention of AF, i.e., reducing the risk of first 
onset by targeting modifiable risk factors (Figure 1), is the 
ultimate goal. However, this approach is challenging due to 
significant knowledge gaps related with understanding the 
multiple mechanisms of AF. Some models such as 
CHARGE-AF have been developed to predict the risk of 
AF, and identify patients who may benefit from preventa-
tive interventions, based on age, race, height, weight, blood 
pressure, smoking, use of antihypertensive medication, dia-
betes, and history of myocardial infarction and heart fail-
ure.[36] However, this model has only been validated for 
populations in the United States and Western Europe.[36] 
There is some evidence of causality between BMI and AF  
 
Figure 5.  AF stages and proposed interventions. Modified 
from the WHF AF roadmap. AF: atrial fibrillation. WHF: world 
hemophilia federation. 
and some intervention studies seem to indicate that out-
comes after AF ablation may be better when modifiable risk 
factors are aggressively approached.[37] Although the bene-
fits of interventions to manage risk factors such as weight, 
blood pressure, smoking and diabetes for health outcomes 
generally are well-established and relevant to populations 
globally, primary prevention trials for AF have yet to estab-
lish a role for interventions for specific risk factors (Figure 5). 
There is an urgent need for research that can inform primary 
prevention efforts for AF in more geographically and ra-
cially diverse populations, while also evaluating the effec-
tiveness of preventative strategies aimed at reducing the risk 
of AF globally.[38] 
4  Screening  
Identifying individuals at risk of developing AF is im-
portant, however, there is stronger evidence that early detec-
tion and treatment of modifiable risk factors can reduce 
morbidity and mortality due to AF. Current guidelines ad-
vocate that “all patients who present with symptoms of 
AF―breathlessness, palpitations, syncope, chest discomfort 
or stroke―should have their pulse checked for irregularities 
as well as 12-lead ECG”.[39] Prolonged ECG monitoring 
may be especially useful in patients with heart failure and 
post-stroke, in order to enhance detection and reduce health 
resource utilization and costs, depending on local resource 
and expertise. The role of routine screening of individuals at 
risk for asymptomatic AF, remains debatable and probably 
untenable as a population intervention. Nonetheless, a re-
cent randomized trial comparing routine practice versus 
targeted population-based screening and opportunistic 
screening, opportunistic palpation (pulse-taking) of patients 
aged 65 and over, with or without known AF risk factors 
(with follow-up ECG for those with an irregular pulse) was 
found to be the cheapest and most effective method of 
screening for AF [opportunistic screening was found to de-
tect similar numbers of new cases compared with systematic 
screening (1.64% vs. 1.62%, and requires fewer resources)].[40] 
One limitation of opportunistic pulse palpation is the high 
number of false positives that can result in unnecessary 
ECGs. A recent meta-analysis has suggested that newer 
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technologies such as modified blood pressure monitors 
(BPMs) and single-lead ECGs may be more accurate in 
detecting AF,[41] and at-home BPMs have been estimated to 
reduce strokes and save costs by the UK National Institute 
of Clinical Evaluation.[42] However, these technologies are 
not widely available and therefore their use for popula-
tion-wide screening initiatives is limited. 
5  Diagnosis 
Although an irregular pulse may point to AF, an ECG is 
still required to confirm the diagnosis. A negative ECG does 
not exclude the diagnosis of AF by pulse-taking since AF 
may be paroxysmal. In patients with suspected AF, diagno-
sis should be confirmed using a single-lead rhythm strip or 
12-lead ECG documenting ≥ 30 s of AF.[43,44] A 12-lead 
ECG can detect other abnormalities such as left ventricular 
hypertrophy, ischemia, and other clinical features. At first 
diagnosis, AF can be classified as one of four types: parox-
ysmal (self-terminating, usually within 48 h), persistent 
(lasts longer than 7 days), long-standing persistent (has lasted 
one year or more) or permanent (when presence of arrhyth-
mia is accepted and no rhythm control, i.e., stabilizing sinus 
rhythm, is attempted). Although paroxysmal AF is associ-
ated with somewhat lesser risk of stroke and systemic em-
bolism than non-paroxysmal AF,[45] all types of AF are as-
sociated with sufficiently increased risk, especially for 
stroke,[46] making detection of even paroxysmal AF critical 
and warranting oral anticoagulation therapy in the majority 
of those aged 65 years or more. Further prolonged monitor-
ing techniques may be indicated but are not cost-effective 
and of limited value from a population based perspec-
tive.[47–50] Inexpensive smart phone-based rhythm monitor-
ing equipment has potential applications in LMIC, but sys-
tems for deployment and validation require further assess-
ment.  
Presence of CVD and other risk factors affects the risk of 
stroke and prognosis in patients with AF, and should be 
systematically assessed. An in-depth discussion of the mul-
tiple risk scores for identification of patients at higher risk of 
stroke is out of the scope of this review. It is important to 
highlight that many of these scores are underutilized by 
primary care physicians and therefore significant propor-
tions of patients globally remain under diagnosed and un-
dertreated with oral anticoagulation therapies and poor con-
trol of modifiable risk factors.  
6  Management policy recommendations 
The role of OACs for the prevention of stroke and sys-
temic embolism in patients with AF is clearly established 
and today several options are available. The main chal-
lenges are related with the perceived threat of bleeding in 
contrast to the prevention of a disabling stroke. Populations 
that derive the greatest benefit from OACs are the elderly 
that are also at higher risk of bleeding; nonetheless multiple 
databases demonstrate the evidence that OACs and most 
likely direct oral anticoagulants are the preferred strategy. 
Anticoagulation for medium- and high-risk non-valvular AF 
is identified as a recommended policy option by the World 
Health Organization (WHO) in the WHO Global Action 
Plan for the Prevention and Control of NCDs 2013–2020.[51] 
Nevertheless, warfarin remains the most widely available 
anticoagulant and is the only anticoagulant on the World 
Health Organization’s Essential Medicines list.[52] Aspirin, 
which is widely used as an antithrombotic therapy for AF is 
neither effective nor safe and has very limited indications 
and is rarely indicated by most guidelines.[53] The combina-
tion of aspirin plus clopidogrel is more effective than aspirin 
alone but less effective than warfarin, and has no advantage 
over warfarin in terms of major bleeding.[54] However, this 
combination may be an alternative particularly in LMIC and 
for patients that live in remote rural areas where proper 
OAC follow-up may be unrealistic.[55] 
The decision to initiate OAC therapy to reduce risk of 
stroke must be weighed against the risk of major bleeding 
complications associated with anticoagulant therapy, the 
most treacherous of which is intra-cerebral hemorrhage.[56] 
The highest the risk of stroke estimated by most risk scores; 
the higher the risk of bleeding. From the population per-
spective implementation of all these scores is impractical 
particularly if detection of subjects at risk in LMIC and rural 
areas globally is primarily implemented by non-physicians. 
A simplistic approach called CHADS 65 implemented by 
the Canadian Cardiovascular Society may be more approa-
chable from the global perspective.[57] 
Monitoring of AF patients by primary health care pro-
viders also presents the opportunity to monitor and treat 
co-morbid cardiovascular conditions,[58,59] in particular hy-
pertension, heart failure, diabetes and valvular abnormalities. 
Valvular AF is not the focus of this review, but nonetheless 
management of AF should include consideration of the 
management of rheumatic heart disease and valvular heart 
disease, which are common in LMIC and associated with 
development of AF in a significant proportion.[60] 
7  The “ideal” patient care pathway for AF 
patients 
The ideal patient care pathway will vary among geogra-
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phies and is primarily based on health resource availability. 
Key global recommendations for detection, diagnosis and 
management of AF, or the “ideal patient pathway” for AF 
patients, are summarized in Figure 2. Stepwise approach 
includes: (1) screening of individuals with known AF risk 
factors and opportunistic screening of patients 65 years or 
older; (2) 12-lead ECG to confirm suspected AF; (3) as-
sessment of stroke risk; and (4) initiation of anticoagulant 
therapy, combined with lifestyle modification advice if ap-
propriate (e.g., weight reduction, smoking cessation). Fur-
ther management strategies are clearly established and are 
not the focus of these recommendations.  
8  Strategies for global AF care improvement 
Several lines of evidence derived from administrative 
databases and registries clearly indicate both under diagno-
sis and under utilization of appropriate guideline recom-
mended therapy of both modifiable risk factors and oral 
anticoagulation. Opportunistic pulse palpation of individuals 
over 65 years of age, with confirmatory ECG,[40] despite 
being documented in only one randomized clinical trial is 
sensible and easily implemented from the population per-
spective. 
The GARFIELD registry, a study of 19 countries in 
2009–2011, revealed that 38.0% of patients with high risk 
of stroke had not received anticoagulant therapy, whereas 
42.5% of those at low risk (score 0) did.[61] The PINNACLE 
Study in the United States found that less than half of 
high-risk patients were receiving OACs therapy.[62] In the 
EURObservational Research Programme-Atrial Fibrillation 
(EORP-AF) general registry of nine European countries, 
while use of OACs was higher (approximately 81% of high 
stroke risk patients), persistence of therapy was still not 
optimal (84% of those prescribed with vitamin K antagonist 
remained on therapy 1 year later), and despite guidelines, 
anti-platelet therapy (commonly aspirin) was used in 15% 
of low risk patients, and in 31% of high-risk patients.[63]  
Treatment and management gaps exist worldwide and 
older populations are the ones at highest risk but remain 
largely untreated due to the perceived risk of bleeding; these 
gaps vary in degree across countries, but are more promi-
nent in LMIC.[64] Data from LMIC are limited and suggest 
very low rates of oral anticoagulation therapy among AF 
patients.[38,59] A few studies reported that estimated rates 
of anticoagulant use range from only 2.7%–50% in 
China,[59,65–67] 26%–44% in Pakistan,[68] 16% in Malaysia,[69] 
46.7%–57.8% in Brazil,[70] 36.8% in Mexico,[71] 72.7% in 
Argentina,[72] 33% in South Africa,[73] 34.2% in Camer-
oon,[74] from 11.5% (rural) to 26.5% (urban) in Zimbabwe,[75] 
62% in Senegal,[76] 30.1%–67.3% in Turkey,[77] 13%–53.9% 
in Serbia,[78] 27% in Kosovo,[79] and 7.1% in Moldova.[80] 
The Gulf SAFE registry revealed similarly low rates of an-
ticoagulation use (49% of patients) in six Gulf countries 
(Bahrain, Kuwait, Oman, Qatar, United Arab Emirates and 
Yemen).[80] 
Most evidence on AF knowledge-practice gaps LMIC 
focuses on gaps in management of stroke risk among AF 
patients with OACs. However, there is evidence of gaps 
across the continuum of care for AF globally, which are 
likely to apply in LMIC. For example, research in Canada 
suggested that non-cardiologist physicians lack sufficient 
knowledge, skills and confidence to diagnose AF, with di-
agnosis of paroxysmal or asymptomatic AF being particularly 
challenging, and that continuous professional education and 
development is necessary to strengthen the capacity of phy-
sicians to navigate AF screening and diagnosis guidelines.[81] 
9  Improving accessibility and availability of 
screening for rural populations 
The World Heart Federation recommends that screening 
for AF is best conducted via opportunistic palpation 
(pulse-taking) of patients aged 65 and over, with or without 
known AF risk factors, with follow up ECG for those with 
an irregular pulse. Following this recommendation may be 
challenging, particularly in remote settings in LMICs, and 
the opportunity to utilize non-physician health professionals 
who are trained to implement novel technologies that allow 
for cardiac rhythm assessment by non-specialist health care 
workers may be feasible.[82] Further studies are needed to 
implement this strategy. 
10  Summary and conclusions 
AF affects millions of people worldwide and, left un-
treated, increases the risk and severity of stroke, heart fail-
ure and death. The global aging of the population will de-
termine an endemic that will result in significant burden on 
health care systems and physicians taking care of these pop-
ulations. There exist significant gaps globally that put 
LMICs at higher risk of negative outcomes that merit a 
global approach that promotes conscious identification and 
management of modifiable risk factors as well as proper risk 
stratification and treatment. Further education of both 
non-specialists and non physician workers may improve 
screening, detection and appropriate management of AF that 
may in turn improve global outcomes. The World Heart 
Federation is committed to promote this approach in an at-
tempt to halt the progression of the inevitable endemic. 
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